Idioma:

Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

De Angelis, Carmine ; Fu, Xiaoyong ; Cataldo, Maria Letizia ; Nardone, Agostina ; Pereira, Resel ; Veeraraghavan, Jamunarani ; Nanda, Sarmistha ; Qin, Lanfang ; Sethunath, Vidyalakshmi ; Wang, Tao ; Hilsenbeck, Susan G ; Benelli, Matteo ; Migliaccio, Ilenia ; Guarducci, Cristina ; Malorni, Luca ; Litchfield, Lacey M ; Liu, Jiangang ; Donaldson, Joshua ; Selenica, Pier ; Brown, David N ; Weigelt, Britta ; Reis-Filho, Jorge S ; Park, Ben H ; Hurvitz, Sara A ; Slamon, Dennis J ; Rimawi, Mothaffar F ; Jansen, Valerie M ; Jeselsohn, Rinath ; Osborne, C Kent ; Schiff, Rachel

Clinical cancer research, 2021-09, Vol.27 (17), p.4870-4882 [Periódico revisado por pares]

United States

Texto completo disponível

Citações Citado por

Enviar para

Título:
Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer
Autor: De Angelis, Carmine ; Fu, Xiaoyong ; Cataldo, Maria Letizia ; Nardone, Agostina ; Pereira, Resel ; Veeraraghavan, Jamunarani ; Nanda, Sarmistha ; Qin, Lanfang ; Sethunath, Vidyalakshmi ; Wang, Tao ; Hilsenbeck, Susan G ; Benelli, Matteo ; Migliaccio, Ilenia ; Guarducci, Cristina ; Malorni, Luca ; Litchfield, Lacey M ; Liu, Jiangang ; Donaldson, Joshua ; Selenica, Pier ; Brown, David N ; Weigelt, Britta ; Reis-Filho, Jorge S ; Park, Ben H ; Hurvitz, Sara A ; Slamon, Dennis J ; Rimawi, Mothaffar F ; Jansen, Valerie M ; Jeselsohn, Rinath ; Osborne, C Kent ; Schiff, Rachel
Assuntos: Antineoplastic Agents - therapeutic use ; Breast Neoplasms - chemistry ; Breast Neoplasms - drug therapy ; Cyclin-Dependent Kinase 4 - antagonists & inhibitors ; Cyclin-Dependent Kinase 6 - antagonists & inhibitors ; Female ; Humans ; Piperazines - therapeutic use ; Pyridines - therapeutic use ; Receptors, Estrogen - analysis ; Signal Transduction ; Tumor Cells, Cultured
É parte de: Clinical cancer research, 2021-09, Vol.27 (17), p.4870-4882
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors (CDK4/6i) are highly effective against estrogen receptor-positive (ER )/HER2 breast cancer; however, intrinsic and acquired resistance is common. Elucidating the molecular features of sensitivity and resistance to CDK4/6i may lead to identification of predictive biomarkers and novel therapeutic targets, paving the way toward improving patient outcomes. Parental breast cancer cells and their endocrine-resistant derivatives (EndoR) were used. Derivatives with acquired resistance to palbociclib (PalboR) were generated from parental and estrogen deprivation-resistant MCF7 and T47D cells. Transcriptomic and proteomic analyses were performed in palbociclib-sensitive and PalboR lines. Gene expression data from CDK4/6i neoadjuvant trials and publicly available datasets were interrogated for correlations of gene signatures and patient outcomes. Parental and EndoR breast cancer lines showed varying degrees of sensitivity to palbociclib. Transcriptomic analysis of these cell lines identified an association between high IFN signaling and reduced CDK4/6i sensitivity; thus an "IFN-related palbociclib-resistance Signature" (IRPS) was derived. In two neoadjuvant trials of CDK4/6i plus endocrine therapy, IRPS and other IFN-related signatures were highly enriched in patients with tumors exhibiting intrinsic resistance to CDK4/6i. PalboR derivatives displayed dramatic activation of IFN/STAT1 signaling compared with their short-term treated or untreated counterparts. In primary ER /HER2 tumors, the IRPS score was significantly higher in lumB than lumA subtype and correlated with increased gene expression of immune checkpoints, endocrine resistance, and poor prognosis. Aberrant IFN signaling is associated with intrinsic resistance to CDK4/6i. Experimentally, acquired resistance to palbociclib is associated with activation of the IFN pathway, warranting additional studies to clarify its involvement in resistance to CDK4/6i.
Editor: United States
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 3 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

United States

Buscando em bases de dados remotas. Favor aguardar.